Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Hemispherx Biopharma Enters into Clinical Trial Agreement with Roswell Park 14
Hemispherx Biopharma and Roswell Park Enter into Collaboration Agreement 15
Hemispherx Biopharma Enters into Agreement with University of Nebraska Medical 16
Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 17
Scientific Products Pharma Enters into Agreement with Hemispherx Biopharma 18
myTomorrows Enters into Agreement with Hemispherx Biopharma 19
Hemispherx Biopharma Amends Agreement with myTomorrows 20
Licensing Agreements 21
Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 21
Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 22
Equity Offering 23
Hemispherx Biopharma Plans to Raise up to USD75 Million in Public Offering of Securities 23
Hemispherx Biopharma to Raise USD2.6 Million in Private Placement of Shares 24
Hemispherx Biopharma to Raise USD0.5 Million in Private Placement of Shares 25
Hemispherx Biopharma Plans to Raise USD1.6 Million in Public Offering of Shares 26
Hemispherx Biopharma Plans to Raise Funds through Private Placement of Shares, upon Exercise of Warrants 27
Hemispherx Biopharma to Raise up to USD1 Million in Private Placement of Shares 28
Hemispherx Biopharma Raises USD0.05 Million in Private Placement of Shares 29
Hemispherx Biopharma Raises USD5 Million in Private Placement of Shares 30
Hemispherx Biopharma to Raise up to USD8 Million in Public Offering of Shares 31
Hemispherx Biopharma Announces Public Offering Of Shares For Up To US$75 Million 33
Hemispherx Biopharma Inc – Key Competitors 34
Hemispherx Biopharma Inc – Key Employees 35
Hemispherx Biopharma Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 15, 2018: Hemispherx announces six months ended June 30, 2018 financial results 37
May 16, 2018: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 38
Apr 02, 2018: Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017 39
Nov 15, 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Nine Months Ended September 30, 2017 40
Aug 15, 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017 41
May 15, 2017: Hemispherx Biopharma Q1 net loss increases 42
Mar 31, 2017: Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 43
Corporate Communications 44
May 31, 2017: Hemispherx Biopharma appoints new deputy chief medical officer 44
Product News 45
12/20/2017: Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen at Contract Manufacturer 45
09/18/2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe 46
08/28/2018: Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order 47
08/24/2018: Hemispherx to present at the 20th annual Rodman & Renshaw Global Investment Conference 48
08/08/2017: Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 49
07/03/2018: Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies 50
06/15/2018: Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot 51
06/05/2018: Hemispherx Announces New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment 52
05/31/2018: Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors 53
05/31/2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities 54
05/31/2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology 55
05/15/2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017 56
04/17/2018: Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs 57
04/04/2018: Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients 58
03/06/2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017 59
03/05/2018: Hemispherx to Present Alferon N Injection at the 30th Annual ROTH Conference 60
03/05/2018: Hemispherx to Present Ampligen at the 30th Annual ROTH Conference 61
02/26/2018: Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program 62
01/26/2018: Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection 63
01/26/2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe 64
01/25/2018: Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors 65
01/23/2018: Hemispherx Comments on $500+ Million Market Opportunity for Ampligen, the Only Late Stage ME/CFS Candidate in the U.S. 66
01/17/2018: Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility 67
01/11/2018: Hemispherx Enhances Manufacturing Efficiency of Ampligen 68
01/11/2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients 69
Product Approvals 70
Jun 27, 2018: Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina 70
Clinical Trials 71
Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine 71
Jan 31, 2018: Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs 72
Jan 09, 2018: Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference 73
Aug 14, 2017: Hemispherx Human Safety Study of Intranasal Ampligen with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated 74
Jul 10, 2017: Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer 75
Other Significant Developments 76
Dec 19, 2017: Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives 76
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hemispherx Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Hemispherx Biopharma Enters into Clinical Trial Agreement with Roswell Park 14
Hemispherx Biopharma and Roswell Park Enter into Collaboration Agreement 15
Hemispherx Biopharma Enters into Agreement with University of Nebraska Medical 16
Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 17
Scientific Products Pharma Enters into Agreement with Hemispherx Biopharma 18
myTomorrows Enters into Agreement with Hemispherx Biopharma 19
Hemispherx Biopharma Amends Agreement with myTomorrows 20
Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 21
Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 22
Hemispherx Biopharma Plans to Raise up to USD75 Million in Public Offering of Securities 23
Hemispherx Biopharma to Raise USD2.6 Million in Private Placement of Shares 24
Hemispherx Biopharma to Raise USD0.5 Million in Private Placement of Shares 25
Hemispherx Biopharma Plans to Raise USD1.6 Million in Public Offering of Shares 26
Hemispherx Biopharma Plans to Raise Funds through Private Placement of Shares, upon Exercise of Warrants 27
Hemispherx Biopharma to Raise up to USD1 Million in Private Placement of Shares 28
Hemispherx Biopharma Raises USD0.05 Million in Private Placement of Shares 29
Hemispherx Biopharma Raises USD5 Million in Private Placement of Shares 30
Hemispherx Biopharma to Raise up to USD8 Million in Public Offering of Shares 31
Hemispherx Biopharma Announces Public Offering Of Shares For Up To US$75 Million 33
Hemispherx Biopharma Inc, Key Competitors 34
Hemispherx Biopharma Inc, Key Employees 35
Hemispherx Biopharma Inc, Other Locations 36
Hemispherx Biopharma Inc, Subsidiaries 36
List of Figures
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11
